Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA NephropathyGlobeNewsWire • 08/27/25
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL InhibitorGlobeNewsWire • 08/13/25
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial OfficerGlobeNewsWire • 08/04/25
Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of DirectorsGlobeNewsWire • 07/21/25
Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business OfficerGlobeNewsWire • 07/10/25
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune AssetGlobeNewsWire • 06/25/25
Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder ValueGlobeNewsWire • 05/08/25
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company UpdateGlobeNewsWire • 03/20/25
Vor Bio Presents Novel Research Highlighting Opportunities and Challenges Facing Institutions Enrolling Patients in Cell and Gene Therapy TrialsGlobeNewsWire • 02/13/25
Vor Bio to Participate in the Oppenheimer's 35th Annual Healthcare Life Sciences ConferenceGlobeNewsWire • 02/03/25
Vor Biopharma Inc. (VOR)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 01/27/25
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of DirectorsGlobeNewsWire • 01/08/25
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial DesignGlobeNewsWire • 12/09/24
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial OfficerGlobeNewsWire • 09/30/24
New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted TherapiesGlobeNewsWire • 09/05/24
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company UpdateGlobeNewsWire • 08/08/24